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Chronic lymphocytic leukemia (CLL) is the most frequent leukemia in Western adults. It was suggested
that transcripts from a reciprocal trans-splicing event between YPEL5 and PPP1CB were present ex-
clusively in CLL patients (more than 90%). Here we show that the YPEL5–PPP1CB fusion is not speciﬁc for
CLL but is also detected in other hematological malignancies such as chronic myeloid leukemia, mono-
clonal B cell lymphocytosis or acute leukemia and also in normal samples. As such, it is unlikely that the
YPEL5–PPP1CB fusion is a good drug target in CLL or a suitable target to monitor disease.
& 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Chronic lymphocytic leukemia (CLL) is the most frequent leu-
kemia in adults in the Western society and is characterized by
accumulation of clonal mature B cells [1–3]. In most patients, CLL
is preceded by a monoclonal B cell lymphocytosis (MBL), char-
acterized by less than 5000 monoclonal B cells/mL in the peripheral
blood [4]. Although most CLL patients have an indolent clinical
course, some cases present with a more aggressive evolution,
leading to high morbidity and mortality [2]. Although several
frequent mutations have been found in CLL [3], there is no com-
mon translocation or mutation known.
Recently, a reciprocal fusion between YPEL5 (yippee-like 5) and
PPP1CB (serine/threonine protein phosphatase-1 beta catalytic
subunit) was described to be exclusively expressed in more than
90% of primary CLL samples [5] and not in control samples or
samples from patients with other hematological malignancies. The
two chimeric RNA transcripts appeared be the result of trans-
splicing as no sign of genomic reorganization could be detected.
The discovery of a common, CLL-speciﬁc molecular defect is in-
teresting as it provides a unique target for drug discovery and
molecular monitoring.
Here, we show that the YPEL5–PPP1CB chimeric transcript is
not speciﬁc for CLL as it is also detected in primary patient samples
of the CLL-precursor MBL, acute myeloid leukemia (AML), acuteLtd. This is an open access article u
andepoele).lymphocytic leukemia (ALL), chronic myeloid leukemia (CML) and
normal samples. As such, it should not be used as a diagnostic
marker and the relevance for this fusion transcript in CLL as a drug
target and molecular marker is questionable.2. Materials and methods
2.1. Samples
Diagnostic or follow-up blood and bone marrow samples from
patients with CLL, MBL, AML, CML and ALL were collected from
February 2012 to September 2013 in the course of normal treat-
ment. Diagnosis was based on the World Health Organization
2008 criteria [2]. Permission to use left-over samples was obtained
from the ethical committee of Ghent University Hospital and all
samples were treated according to the Declaration of Helsinki.
White blood cells were isolated by erythrocyte lysis. RNA was
isolated using the RNeasy kit (Qiagen) according to the manufac-
turer's instructions.2.2. cDNA synthesis
cDNA was made using SuperScript II or SuperScript III (Life
Technologies) according to the manufacturer's instructions. Brieﬂy,
1 mg RNA was reverse transcribed in a total volume of 40 (Super-
Script II) or 50 mL (SuperScript III).nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
K. Vandepoele et al. / Leukemia Research Reports 4 (2015) 51–54522.3. qPCR
For the NuPCR (Illumina; product discontinued), primers and
MNAzyme were designed with the DesignStudio. YPEL5-PPP1CB and
PPP1CB–YPEL5 PCRs (both with FAM-labeled probe) were performed
in a two multiplex PCRs, each in combination with an ABL1 PCR (HEX-
labeled probe). The primers used are: 5′-TAAACCTGGAGACTCGGGTGG-
3′ and 5′-CTTTCCTGGACGACATCCTCGTA-3′ for YPEL5-PPP1CB, 5′-
AGTCTGTGCCGACAAGATGGC-3′ and 5′-TCCATCTGTCAAGACGACGTA-
GAATAAAA-3′ for PPP1CB-YPEL5 and 5′-CAGAGGTCCATCTCGCTGAGA-
TA-3′ and 5′-CTCGGAGGAGACGTAGAGCTT-3′ for ABL1. The sequence of
the MNAzymes were not provided by the manufacturer. The NuPCR
was performed according to the manufacturer's instructions. Brieﬂy,
5 mL cDNAwas used in a 20 mL total reaction volume. Cycling was done
on a CFX96 cycler (Bio-Rad) following this protocol: 95 °C 2min, 40
cycles of 95 °C for 15 s, 50 °C for 30 s and 72 °C for 30 s.
For the EvaGreen qPCR, we used the published SYBR Green
assay primers [5] for YPEL5–PPP1CB and 5′-TGACAGGGGA-
CACCTACACA-3′ and 5′-ATACTCCAAATGCCCAGACG-3′ for ABL1 in
combination with the SsoFast EvaGreen Supermix (Bio-Rad). For
the PCR, 5 mL cDNAwas used in a 20 mL total reaction volume using
300 nM primers. Cycling was done on a CFX96 cycler (Bio-Rad)
with the following PCR protocol: 95 °C for 30 s and 50 cycles of
95 °C for 5 s and 60 °C for 20 s. Following the PCR, a melting curve
from 65 °C to 95 °C was done (0.5 °C/5 s).
For both PCR strategies, expression of YPEL5–PPP1CB was
normalized to the expression of ABL1. All PCRs included proper
negative controls, which never showed ampliﬁcation. Samples
were analyzed for tumor-speciﬁc markers (e.g. BCR–ABL1 ex-
pression in CML samples) to conﬁrm their identity as non-CLL
samples.3. Results and discussion
The apparent frequent and exclusive occurrence of the trans-
splicing of YPEL5 and PPP1CB in CLL [5] could be a good target for
directed therapy and molecular monitoring of this disease. To
maximize the sensitivity and speciﬁcity in the detection of this
fusion transcript, we used the recently introduced NuPCR techni-
que [6]. The combination of two speciﬁc primers and a speciﬁc
MNAzyme ensures a high speciﬁcity of the PCR in combination
with a sensitive detection method (Fig. 1).
Initially, we tested four samples of CLL patients for the ex-
pression of both YPEL5–PPP1CB and PPP1CB–YPEL5 transcripts. In
all samples, we observed low expression of the YPEL5–PPP1CB
transcript. In contrast, the PPP1CB–YPEL5 transcript was not de-
tected in any sample (data not shown). Therefore, we focused on
the YPEL5–PPP1CB transcript in our further analyses. The panel of
primary diagnostic CLL samples was expanded and in total, we
detected variable expression of the YPEL5–PPP1CB transcript inFig. 1. Location of primers and probes. The chimeric transcript starts with the ﬁrst exon
used in the analyses are shown as arrows.17/18 CLL samples (94%) (Fig. 2A – black bars), conﬁrming the
recurrent expression of the YPEL5–PPP1CB transcript in CLL [5].
To test the speciﬁcity of the expression of YPEL5–PPP1CB, we
tested diagnostic samples of patients with AML (n¼3), ALL (n¼4),
MBL (n¼7), CML (n¼3), different hematological cell lines (n¼10;
data not shown) and samples from healthy individuals (n¼3) with
the NuPCR for YPEL5–PPP1CB. All patient samples and three cell
lines (ME-1, Kasumi-1, and MonoMac-6) tested positive, albeit at
different levels (Fig. 3A – black bars), showing that the presence of
YPEL5–PPP1CB is not speciﬁc for CLL. The expression levels in the
different sample types were highly variable, but correspond to the
levels observed in primary CLL samples. To investigate the dis-
crepancy between the NuPCR and the results obtained by Velu-
samy et al. [5], we repeated the analysis on the same samples with
the primers from the published SYBR Green assay [5] (Fig. 1; fur-
ther referred to as EvaGreen method). After the PCR, one melting
peak was obtained and sequence analysis conﬁrmed the identity
of the YPEL5–PPP1CB fusion (Supplementary Fig. S1). The patient
samples showed similar expression with the EvaGreen method as
obtained by the NuPCR (Figs. 2A and 3A – white bars). This con-
ﬁrmed the wide expression in non-CLL samples, disproving the
statement that the YPEL5–PPP1CB is speciﬁc for CLL. Globally, the
expression level was comparable regardless of the PCR technique
used (Figs. 2B and 3B).
A report on high-throughput mRNA sequencing in CLL patients
[7] also described a low-level expression of the YPEL5–PPP1CB
transcript, both in normal and cancer samples. Although the ex-
pression level was below the threshold set by the authors, this
ﬁnding is concordant with our results.
The discrepancy between our results and the results from Ve-
lusamy et al. [5] is potentially explained by the recent ﬁnding that
incubation-induced gene dysregulation affects the expression level
and splicing of numerous genes in leukemic samples [8]. As the
expression level of YPEL5–PPP1CB is very low, even small differ-
ences in splicing efﬁciency, as a result of different sample pro-
cessing times, could make the difference between being able to
detect the transcript or not.
To conclude, we ﬁnd that the YPEL5–PPP1CB transcript is not
exclusively present in CLL samples and its usability as a molecular
marker and the relevance for CLL therapeutics should be scruti-
nized thoroughly before taking steps in the development of target-
speciﬁc drugs.Authors’ contributions
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the ﬁnal version.of YPEL5 (black) and is followed by the second exon of PPP1CB (gray). The primers
Fig. 2. Expression of YPEL5–PPP1CB in diagnostic samples of CLL patients. (A) Diagnostic CLL samples (n¼17) were analyzed for YPEL5–PPP1CB expression using two
different PCR strategies (NuPCR (black) and EvaGreen (white)). The relative expression is highly variable but shows overall a good comparison between the two techniques
used. Only positive samples with quantiﬁable results are shown. The expression in the sample CLL1 was set to 1 and all other samples are shown relative to this sample.
(B) Scatter plot comparing the results from the NuPCR with the EvaGreen PCR. A correlation coefﬁcient of 0.9676 was obtained.
Fig. 3. Expression of YPEL5–PPP1CB in diagnostic and remission samples of patients with different hematological malignancies. (A) Diagnostic AML (n¼3), ALL (n¼4), CML
(n¼3), and MBL (n¼7) samples, and normal bone marrow samples (n¼3) were analyzed for YPEL5–PPP1CB expression using two different PCR strategies (NuPCR (black)
and EvaGreen (white)). CLL1 and CLL2 samples are reproduced from Fig. 2 for comparison. All samples show expression levels in the same range as the CLL samples. The
expression in the sample CLL1 was set to 1 and all other samples are shown relative to this sample. (B) Scatter plot comparing the results from the NuPCR with the EvaGreen
PCR. A correlation coefﬁcient of 0.6945 was obtained.
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